A regulatory decision on the combination therapy is expected on February 8, 2025. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback